In light of the FLAURA2 data, which patients would you recommend upfront treatment with chemotherapy + osimertinib rather than osimertinib monotherapy?
Community PollStarted
Which of the following subsets of patients with advanced EGFR-mutated NSCLC would you consider addition of platinum-based chemotherapy to osimertinib?
101 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Albert Einstein College of Medicine at Montefiore Medical Center
Answered on
The management of patients with advanced, classical (i.e., exon 19 deletion/L858R) EGFR mutation-positive NSCLC has been fairly straightforward since the approval of osimertinib for frontline management based on the outstanding results of the FLAURA study demonstrating significantly improved PFS and...
Join for free or sign in to see the full answer